{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-22-009385","form_type":"8-K","ticker":"ZIVO","cik":"0001101026","company_name":"Zivo Bioscience, Inc.","filed_at":"2022-07-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:54.982671+00:00","generated_at":"2026-06-24T18:59:16.463313+00:00","sec_items":["5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Zivo Bioscience adopts staggered board, eliminates shareholder written consent","bullets":["Board approved Second Amended and Restated Bylaws effective June 30, 2022.","Creates three-class staggered board; only one class elected per annual meeting after initial election.","Eliminates stockholder ability to take action by written consent.","Only the Board may appoint directors to fill vacancies or change the number of directors.","Adds modernizing provisions for electronic meetings and access to corporate records."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-22-009385","json":"https://secwatch.observer/filing/0001654954-22-009385.json","markdown":"https://secwatch.observer/filing/0001654954-22-009385.md","text":"https://secwatch.observer/filing/0001654954-22-009385.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1101026/000165495422009385/0001654954-22-009385-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1101026/000165495422009385/zivo_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T18:59:16.463313+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}